A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Roswell Park Cancer Institute
Vejle Hospital
City of Hope Medical Center
First Affiliated Hospital of Guangxi Medical University
Memorial Sloan Kettering Cancer Center
Pfizer
NRG Oncology
Sun Yat-sen University
Institut du Cancer de Montpellier - Val d'Aurelle
University of Kansas Medical Center
Rutgers, The State University of New Jersey